The KHI mission is to advance scientific understanding of the kidney health and patient safety implications of new and existing medical products, and to foster development of therapies for diseases that affect the kidney. The initiative plans to achieve this by creating a collaborative environment in which the FDA and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.
“The decision to join the ASN Kidney Health Initiative is an important element in our expanded commitment to the nephrology field,” said Clinipace President and CEO Jeff Williams. “We fully support the KHI goal of improving patient safety and promoting development of new therapies for all patients with kidney disease, a major public health issue that affects up to 26 million Americans.”
